Business Context and Reporting Period
This Form 8-K was filed by Coherus BioSciences, Inc. (CHRS) on February 22, 2024, reporting events occurring on February 20, 2024. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten members.
- New Appointment: Georgia Erbez was appointed as a Class III director to fill the vacancy created by the board expansion.
- Committee Assignment: Ms. Erbez was appointed to serve on the Audit Committee.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for the new director, Georgia Erbez:
- Cash Retainer: An annual cash retainer of $50,000.
- Equity Grant: An option to purchase 54,000 shares of common stock under the 2014 Equity Incentive Award Plan.
- Exercise Price: Set at the closing price of the common stock on the date of appointment (February 20, 2024).
- Vesting Schedule: Options vest in substantially equal monthly installments over three years, contingent on continued service.
- Indemnification: The Company expects to enter into a standard director and officer indemnification agreement.
No financial guidance, outlook, or discussion of risks and contingencies is provided in this specific filing.
Investor Verification Checklist
- Verify the closing stock price on February 20, 2024, to determine the exercise price of the 54,000 share option granted to Ms. Erbez.
- Review the Company's non-employee director compensation policy for details on the $50,000 annual retainer.
- Confirm the total number of outstanding options and shares reserved under the 2014 Equity Incentive Award Plan following this grant.
- Check subsequent filings for the formal execution of the indemnification agreement referenced in the report.